Abediterol produced dose-dependent improvements in peak FEV1 from baseline compared with placebo , from 0.274 ( 95 % CI 0.221 , 0.327 ) to 0.405 L ( 95 % CI 0.353 , 0.458 ) for abediterol 0.313 to 2.5 g , respectively ( p < 0.0001 all doses ) .